What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Tiziano Barbui mostly deals with Internal medicine, Surgery, Polycythemia vera, Essential thrombocythemia and Gastroenterology.
His study connects Immunology and Internal medicine.
His research on Polycythemia vera also deals with topics like
- Aspirin and related Myocardial infarction,
- Phlebotomy and related Acute leukemia.
In his research, Severity of illness is intimately related to Young adult, which falls under the overarching field of Essential thrombocythemia.
Tiziano Barbui has researched Gastroenterology in several fields, including Lymphoproliferative disorders, Neutropenia, Retrospective cohort study, Pathology and Vascular disease.
His studies in Thrombosis integrate themes in fields like Platelet and Leukocytosis.
His most cited work include:
- Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor (1174 citations)
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (1114 citations)
- Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature (763 citations)
What are the main themes of his work throughout his whole career to date?
Tiziano Barbui focuses on Internal medicine, Gastroenterology, Polycythemia vera, Surgery and Essential thrombocythemia.
Tiziano Barbui combines subjects such as Immunology and Oncology with his study of Internal medicine.
His research in Gastroenterology intersects with topics in Chemotherapy regimen, Chemotherapy, Retrospective cohort study, Rituximab and Bone marrow.
His Polycythemia vera study combines topics in areas such as Clinical trial, Hematocrit, Phlebotomy, Aspirin and Acute leukemia.
His research ties Hazard ratio and Surgery together.
His Essential thrombocythemia study integrates concerns from other disciplines, such as Allele, Thrombocytosis and Pathology.
He most often published in these fields:
- Internal medicine (64.71%)
- Gastroenterology (29.41%)
- Polycythemia vera (27.27%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (64.71%)
- Polycythemia vera (27.27%)
- Myelofibrosis (21.75%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Polycythemia vera, Myelofibrosis, Essential thrombocythemia and Thrombosis.
His Internal medicine study incorporates themes from Gastroenterology and Oncology.
His Polycythemia vera study combines topics from a wide range of disciplines, such as Incidence, MEDLINE, Hematocrit, Post-Essential Thrombocythemia Myelofibrosis and Phlebotomy.
The Myelofibrosis study combines topics in areas such as Survival rate, Surgery, Transplantation, Anemia and Univariate analysis.
His research integrates issues of Adverse effect, Prospective cohort study, Quality of life and Thrombocytosis in his study of Essential thrombocythemia.
He has included themes like Odds ratio, Clinical trial and Leukocytosis in his Thrombosis study.
Between 2016 and 2021, his most popular works were:
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet (185 citations)
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. (158 citations)
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. (127 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
His scientific interests lie mostly in Internal medicine, Polycythemia vera, Essential thrombocythemia, Myelofibrosis and Thrombosis.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Oncology.
He interconnects Refractory and Thrombocytosis in the investigation of issues within Gastroenterology.
His Polycythemia vera research incorporates themes from Hematology, Disease, Phlebotomy, Who criteria and Pediatrics.
His Essential thrombocythemia research incorporates elements of Chronic neutrophilic leukemia, Ruxolitinib and PTX3.
The study incorporates disciplines such as Risk assessment, Survival analysis, Surgery, Transplantation and Young adult in addition to Myelofibrosis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
